Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

Parkinson Disease Clinical Trial

Official title:

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04728295
• Other study ID #: PD014
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 14, 2021
• Est. completion date: April 1, 2024

Study information

• Verified date: June 2022
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the Safety and Effectiveness of Staged Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD).

Description:

This study is a prospective, open label, single-arm, multi-center clinical trial to establish the safety and effectiveness of bilateral PTTractotomy for the treatment of motor complications in patients with bilateral idiopathic Parkinson's Disease. A maximum of 50 subjects will be treated at up to 10 sites.

Subjects will undergo an Exablate index procedure targeting the PTT and will be seen at 1-week,1-, 3-, and 6- months post treatment. At the 6-month visit, subjects will be evaluated for an Exablate procedure on the other side.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 50
• Est. completion date: April 1, 2024
• Est. primary completion date: April 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Men and women, age 30 years and older, desiring bilateral treatment option with second side staged at 6 months.

• Subject is able and willing to give informed consent and able to attend all study visits

• Subject with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site.

• Motor complications of PD on optimum medical treatment

• Subject is on a stable dose of all PD medications for 30 days prior to screening visit

• Subject is able to communicate sensations during the Exablate procedure.

Exclusion Criteria:

• Subject where there is suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.

• Subject with significant cognitive impairment as determined by the neuropsychologist.

• Subject has other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.

• Subject with unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation

• Women of childbearing potential who are pregnant or lactating

• Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse

• Subject with unstable cardiac status or severe hypertension including:

• Documented myocardial infarction within six months of enrollment

• Unstable angina on medication

• Unstable or worsening congestive heart failure

• Left ventricular ejection fraction below the lower limit of normal

• History of a hemodynamically unstable cardiac arrhythmia

• Cardiac pacemaker

• Diastolic BP > 100 on medication

• Subject with history of abnormal bleeding, hemorrhage, or coagulopathy including:

• Subject with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter; a documented clinical coagulopathy; or INR coagulation studies exceeding the institution's laboratory standard.

• History of intracranial hemorrhage, multiple strokes, or a stroke within past 6 months

• Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment

• Subject is receiving anticoagulant (e.g., warfarin) or antiplatelet (e.g., aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g., Avastin) within one month of focused ultrasound procedure.

• Subject with severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis.

• Subjects with a history of seizures within the past year.

• Subject with an intracranial brain tumor

• Subjects with life-threatening systemic disease that include and not limited to the following will be excluded from the study participation: HIV, liver failure, blood dyscrasias, etc.

• Any illness that in the investigator's opinion preclude participation in this study.

• Subject with standard contraindications for MR imaging such as implanted metallic devices

• Subject who had prior deep brain stimulation of the basal ganglia or thalamus.

• Subjects who are unable to tolerate the required prolonged stationary supine position during treatment.

• Subject who is participating in another clinical investigation with an active treatment arm in the last 30 days.

• Subject who is unable to communicate with the investigator and staff.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Device:
• Exablate 4000
Exablate Pallidothalamic Tractotomy

Locations

Country	Name	City	State
Spain	Neurology, Hospital Universitario HM Puerta del Sur (HM CINAC)	Madrid
Spain	Clínica Universidad de Navarra	Pamplona
Taiwan	Chang Bing Show Chwan Memorial Hospital	Lugang	Changhua County
United States	University of Maryland, Baltimore	Baltimore	Maryland
United States	Rush University Medical Center	Chicago	Illinois
United States	Delray Medical Center	Delray Beach	Florida
United States	New York University Langone	New York	New York
United States	Weill Cornell Medicine	New York	New York
United States	Stanford	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Countries where clinical trial is conducted

United States,  Spain,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part III OFF Medication	OFF-medication, Upper + Lower Extremity motor score from the MDS-UPDRS Part III comparing all visits post Bilateral treatment to Baseline. Lower score on the scale means a better outcome.	Up to Month 12 post Bilateral Treatment
Other	MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part IV	MDS-UPDRS Part IV at all Bilateral visits comparing all visits post Bilateral treatment to Baseline. Lower score on the scale means a better outcome.	Up to Month 12 post Bilateral Treatment
Primary	MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part III OFF Medication	OFF-medication, Upper + Lower Extremity motor score from the MDS-UPDRS Part III comparing Month 3 post Bilateral treatment to Baseline. Lower score on the scale means a better outcome.	Up to Month 3 post Bilateral Treatment
Secondary	MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part II	MDS-UPDRS Part II - Activities of Daily living comparing all Bilateral scheduled visits to Baseline. Lower score on the scale means a better outcome.	Up to Month 12 post Bilateral Treatment